↓ Skip to main content

Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis

Overview of attention for article published in BMC Psychiatry, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
7 news outlets
policy
3 policy sources
twitter
96 X users
facebook
2 Facebook pages
googleplus
1 Google+ user
reddit
1 Redditor

Citations

dimensions_citation
117 Dimensions

Readers on

mendeley
172 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis
Published in
BMC Psychiatry, July 2017
DOI 10.1186/s12888-017-1419-7
Pubmed ID
Authors

Emily Peckham, Sally Brabyn, Liz Cook, Garry Tew, Simon Gilbody

Abstract

People with severe mental ill health are more likely to smoke than those in the general population. It is therefore important that effective smoking cessation strategies are used to help people with severe mental ill health to stop smoking. This study aims to assess the effectiveness and cost -effectiveness of smoking cessation and reduction strategies in adults with severe mental ill health in both inpatient and outpatient settings. This is an update of a previous systematic review. Electronic databases were searched during September 2016 for randomised controlled trials comparing smoking cessation interventions to each other, usual care, or placebo. Data was extracted on biochemically-verified, self-reported smoking cessation (primary outcome), as well as on smoking reduction, body weight, psychiatric symptom, and adverse events (secondary outcomes). We included 26 trials of pharmacological and/or behavioural interventions. Eight trials comparing bupropion to placebo were pooled showing that bupropion improved quit rates significantly in the medium and long term but not the short term (short term RR = 6.42 95% CI 0.82-50.07; medium term RR = 2.93 95% CI 1.61-5.34; long term RR = 3.04 95% CI 1.10-8.42). Five trials comparing varenicline to placebo showed that that the addition of varenicline improved quit rates significantly in the medium term (RR = 4.13 95% CI 1.36-12.53). The results from five trials of specialised smoking cessation programmes were pooled and showed no evidence of benefit in the medium (RR = 1.32 95% CI 0.85-2.06) or long term (RR = 1.33 95% CI 0.85-2.08). There was insufficient data to allowing pooling for all time points for varenicline and trials of specialist smoking cessation programmes. Trials suggest few adverse events although safety data were not always reported. Only one pilot study reported cost effectiveness data. Bupropion and varenicline, which have been shown to be effective in the general population, also work for people with severe mental ill health and their use in patients with stable psychiatric conditions. Despite good evidence for the effectiveness of smoking cessation interventions for people with severe mental ill health, the percentage of people with severe mental ill health who smoke remains higher than that for the general population.

X Demographics

X Demographics

The data shown below were collected from the profiles of 96 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 172 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 172 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 29 17%
Student > Bachelor 22 13%
Student > Ph. D. Student 20 12%
Researcher 18 10%
Other 12 7%
Other 32 19%
Unknown 39 23%
Readers by discipline Count As %
Medicine and Dentistry 39 23%
Psychology 27 16%
Nursing and Health Professions 25 15%
Social Sciences 6 3%
Unspecified 6 3%
Other 20 12%
Unknown 49 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 123. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2022.
All research outputs
#338,897
of 25,425,223 outputs
Outputs from BMC Psychiatry
#85
of 5,466 outputs
Outputs of similar age
#7,171
of 324,756 outputs
Outputs of similar age from BMC Psychiatry
#5
of 110 outputs
Altmetric has tracked 25,425,223 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,466 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,756 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 110 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.